View Future GrowthFoosung 過去の業績過去 基準チェック /26Foosungの収益は年間平均-50.6%の割合で減少していますが、 Chemicals業界の収益は年間 増加しています。収益は年間1.4% 5.9%割合で 増加しています。 Foosungの自己資本利益率は1.8%であり、純利益率は1.1%です。主要情報-50.64%収益成長率-49.51%EPS成長率Chemicals 業界の成長13.95%収益成長率5.94%株主資本利益率1.81%ネット・マージン1.13%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 21Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩668 loss per share (further deteriorated from ₩556 loss in FY 2023). Revenue: ₩437.8b (down 16% from FY 2023). Net loss: ₩69.4b (loss widened 29% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩1,047 (up from ₩244 in FY 2021). Revenue: ₩610.6b (up 60% from FY 2021). Net income: ₩97.0b (up 330% from FY 2021). Profit margin: 16% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 25Full year 2020 earnings released: EPS ₩65.00 (vs ₩87.00 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩261.6b (up 5.1% from FY 2019). Net income: ₩5.99b (down 26% from FY 2019). Profit margin: 2.3% (down from 3.3% in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.すべての更新を表示Recent updatesMajor Estimate Revision • May 19Consensus EPS estimates fall by 28%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from ₩564.8m to ₩592.8m. EPS estimate fell from ₩288 to ₩206 per share. Net income forecast to grow 316% next year vs 62% growth forecast for Chemicals industry in South Korea. Consensus price target of ₩20,000 unchanged from last update. Share price fell 4.6% to ₩11,830 over the past week.New Risk • May 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change).Buy Or Sell Opportunity • May 04Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 69% to ₩14,130. The fair value is estimated to be ₩11,060, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 52% per annum over the same time period.Major Estimate Revision • Apr 24Consensus EPS estimates increase by 57%, revenue downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from ₩579.5m to ₩564.8m. EPS estimate rose from ₩183 to ₩288. Net income forecast to grow 482% next year vs 62% growth forecast for Chemicals industry in South Korea. Consensus price target up from ₩12,000 to ₩20,000. Share price fell 5.4% to ₩13,070 over the past week.New Risk • Apr 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.0x net interest cover). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Earnings have declined by 57% per year over the past 5 years.分析記事 • Jan 28Foosung Co., Ltd. (KRX:093370) Not Lagging Industry On Growth Or PricingWhen you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...分析記事 • Oct 28Revenues Tell The Story For Foosung Co., Ltd. (KRX:093370) As Its Stock Soars 62%Despite an already strong run, Foosung Co., Ltd. ( KRX:093370 ) shares have been powering on, with a gain of 62% in the...New Risk • Oct 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change).お知らせ • Oct 24Foosung Co., Ltd. announced that it expects to receive KRW 27 billion in fundingFoosung Co., Ltd. announced private placement of Series 2 Zero Coupon Registered Unsecured Private Convertible Bonds due November 05, 2030 for gross proceeds of KRW 27,000,000,000 on October 23, 2025. The transaction includes participation from Heimdall No.2 PEF for KRW 20,000,000,000 and Fluoro Mateiral New Technology Fund for KRW 7,000,000,000. The bonds bear no interest rate and have a yield to maturity rate of 5.7%. The bonds will mature on November 05, 2030. The bonds are 100% convertible into 3,937,582 shares at a conversion price of KRW 6,857 from the conversion period of November 05, 2026 to October 05, 2030. The bonds have a restriction period of 1 year. The transaction is approved by board of directors of the company and is expected to close on November 05, 2025.分析記事 • Oct 17There's Been No Shortage Of Growth Recently For Foosung's (KRX:093370) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...New Risk • Sep 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.7x net interest cover). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).分析記事 • Aug 18Foosung Co., Ltd. (KRX:093370) Stocks Shoot Up 30% But Its P/S Still Looks ReasonableKOSE:A093370 1 Year Share Price vs Fair Value Explore Foosung's Fair Values from the Community and select yours Despite...分析記事 • Aug 14Is Foosung (KRX:093370) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jun 10Potential Upside For Foosung Co., Ltd. (KRX:093370) Not Without RiskThere wouldn't be many who think Foosung Co., Ltd.'s ( KRX:093370 ) price-to-sales (or "P/S") ratio of 1.2x is worth a...Major Estimate Revision • May 02Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩567.0m to ₩550.9m. Now expected to report a loss of ₩49.00 per share instead of ₩69.00 per share profit previously forecast. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩14,000 to ₩10,000. Share price was steady at ₩4,400 over the past week.Reported Earnings • Mar 21Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩668 loss per share (further deteriorated from ₩556 loss in FY 2023). Revenue: ₩437.8b (down 16% from FY 2023). Net loss: ₩69.4b (loss widened 29% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.分析記事 • Mar 18Would Foosung (KRX:093370) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Feb 19Foosung Co., Ltd., Annual General Meeting, Mar 25, 2025Foosung Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 72-37, hyundaikia-ro, paltan-myeon, gyeonggi-do, hwaseong South KoreaNew Risk • Jan 24New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk High level of debt (67% net debt to equity).分析記事 • Nov 23The Price Is Right For Foosung Co., Ltd. (KRX:093370)When you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...分析記事 • Aug 05Foosung Co., Ltd.'s (KRX:093370) Share Price Is Still Matching Investor Opinion Despite 29% SlumpThe Foosung Co., Ltd. ( KRX:093370 ) share price has fared very poorly over the last month, falling by a substantial...Major Estimate Revision • May 24Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩612.4m to ₩516.6m. Forecast loss of -₩107, down from profit of ₩91.00 per share profit previously. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩20,000 to ₩17,000. Share price fell 3.6% to ₩7,010 over the past week.New Risk • May 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Shareholders have been diluted in the past year (14% increase in shares outstanding).お知らせ • Jan 26Foosung Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 101.290324 billion.Foosung Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 101.290324 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,903,226 Price\Range: KRW 7850 Discount Per Security: KRW 39.25 Transaction Features: ESOP Related Offering; Rights OfferingValuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,620, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 28% over the past three years.Upcoming Dividend • Dec 20Upcoming dividend of ₩20.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).New Risk • Aug 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.8% Last year net profit margin: 14% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). High level of non-cash earnings (26% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (5.8% net profit margin).New Risk • Aug 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Earnings are forecast to decline by an average of 0.1% per year for the foreseeable future. High level of non-cash earnings (22% accrual ratio).Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩16,620, the stock trades at a trailing P/E ratio of 16.2x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 174% over the past three years.Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩1,047 (up from ₩244 in FY 2021). Revenue: ₩610.6b (up 60% from FY 2021). Net income: ₩97.0b (up 330% from FY 2021). Profit margin: 16% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Dec 21Upcoming dividend of ₩15.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 07 April 2023. Payout ratio is a comfortable 2.0% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Buying Opportunity • Sep 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be ₩15,184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to grow by 37% in 2 years. Earnings is forecast to grow by 58% in the next 2 years.Buying Opportunity • Aug 05Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be ₩20,863, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 45% in 2 years. Earnings is forecast to grow by 88% in the next 2 years.Buying Opportunity • Jul 12Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 23%. The fair value is estimated to be ₩20,767, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 45% in 2 years. Earnings is forecast to grow by 88% in the next 2 years.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩17,900, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 157% over the past three years.Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩26,250, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 263% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩19,850, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 141% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩18,551 per share.分析記事 • May 09Are Investors Undervaluing Foosung Co., Ltd. (KRX:093370) By 46%?Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Foosung Co., Ltd...分析記事 • Apr 19Foosung (KRX:093370) Use Of Debt Could Be Considered RiskyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Mar 25Full year 2020 earnings released: EPS ₩65.00 (vs ₩87.00 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩261.6b (up 5.1% from FY 2019). Net income: ₩5.99b (down 26% from FY 2019). Profit margin: 2.3% (down from 3.3% in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.分析記事 • Mar 08Here's What To Make Of Foosung's (KRX:093370) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...お知らせ • Feb 27Foosung Co., Ltd., Annual General Meeting, Mar 30, 2021Foosung Co., Ltd., Annual General Meeting, Mar 30, 2021, at 10:00 Korea Standard Time.分析記事 • Feb 14Is Foosung's (KRX:093370) 184% Share Price Increase Well Justified?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...分析記事 • Jan 24Are Investors Undervaluing Foosung Co., Ltd. (KRX:093370) By 25%?How far off is Foosung Co., Ltd. ( KRX:093370 ) from its intrinsic value? Using the most recent financial data, we'll...Is New 90 Day High Low • Jan 19New 90-day high: ₩13,150The company is up 41% from its price of ₩9,300 on 21 October 2020. The South Korean market is up 26% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 35% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩17,381 per share.分析記事 • Jan 02Foosung (KRX:093370) Has A Somewhat Strained Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Dec 18New 90-day high: ₩11,500The company is up 10.0% from its price of ₩10,500 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period.分析記事 • Dec 06Do Institutions Own Foosung Co., Ltd. (KRX:093370) Shares?A look at the shareholders of Foosung Co., Ltd. ( KRX:093370 ) can tell us which group is most powerful. Institutions...収支内訳Foosung の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSE:A093370 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Dec 25471,5645,31244,51710,97230 Sep 25462,733-82,04944,57711,36830 Jun 25448,619-96,49145,50810,84131 Mar 25436,341-62,45646,64510,81931 Dec 24437,795-69,35846,05711,15830 Sep 24433,435-32,61546,16610,75930 Jun 24450,433-38,76643,48810,82231 Mar 24478,526-57,16844,42111,70131 Dec 23523,192-53,91741,69811,73130 Sep 23566,21010,79639,66913,91930 Jun 23595,56534,69941,30214,43931 Mar 23605,21458,52038,03617,94631 Dec 22610,56497,04936,27817,74330 Sep 22596,53671,20334,93617,87030 Jun 22550,81774,53532,15417,07931 Mar 22476,62561,28630,53512,33831 Dec 21381,25722,56429,54211,74730 Sep 21314,47031,48428,7129,18830 Jun 21277,86313,96227,1488,76331 Mar 21264,8107,54026,1538,73631 Dec 20261,6009,97726,1378,48230 Sep 20251,433-5,13827,9088,09830 Jun 20244,270-1,34527,0047,85431 Mar 20245,2961,82226,5137,40831 Dec 19248,9448,10026,0917,19530 Sep 19256,63518,65423,3717,43630 Jun 19261,84920,31222,2686,97431 Mar 19269,12528,35521,6406,47731 Dec 18274,93430,83220,8065,86930 Sep 18266,99525,42419,4045,51830 Jun 18263,81929,03119,5575,36531 Mar 18258,83724,22919,6645,40831 Dec 17248,83829,49718,8365,52430 Sep 17238,52872,22718,1775,31330 Jun 17223,86869,25017,5835,07531 Mar 17204,08971,10416,2564,80631 Dec 16192,07365,52416,0414,59030 Sep 16147,02827,49411,9784,15230 Jun 16152,81322,7079,3626,15031 Mar 16160,29218,12814,1994,25531 Dec 15161,15413,75915,1024,19030 Sep 15204,575-51,86919,8094,00730 Jun 15192,891-56,06223,5301,863質の高い収益: A093370は 高品質の収益 を持っています。利益率の向上: A093370過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A093370の収益は過去 5 年間で年間50.6%減少しました。成長の加速: A093370は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: A093370昨年収益を上げたため、昨年の収益成長をChemicals業界 ( -3.4% ) と比較することは困難です。株主資本利益率高いROE: A093370の 自己資本利益率 ( 1.8% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 06:25終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Foosung Co., Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Rok-ho KimDaishin Securities Co. Ltd.Yumi KimDaiwa Securities Co. Ltd.Byung Hwa HanEugene Investment & Securities Co Ltd.4 その他のアナリストを表示
Reported Earnings • Mar 21Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩668 loss per share (further deteriorated from ₩556 loss in FY 2023). Revenue: ₩437.8b (down 16% from FY 2023). Net loss: ₩69.4b (loss widened 29% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩1,047 (up from ₩244 in FY 2021). Revenue: ₩610.6b (up 60% from FY 2021). Net income: ₩97.0b (up 330% from FY 2021). Profit margin: 16% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 25Full year 2020 earnings released: EPS ₩65.00 (vs ₩87.00 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩261.6b (up 5.1% from FY 2019). Net income: ₩5.99b (down 26% from FY 2019). Profit margin: 2.3% (down from 3.3% in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • May 19Consensus EPS estimates fall by 28%, revenue upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from ₩564.8m to ₩592.8m. EPS estimate fell from ₩288 to ₩206 per share. Net income forecast to grow 316% next year vs 62% growth forecast for Chemicals industry in South Korea. Consensus price target of ₩20,000 unchanged from last update. Share price fell 4.6% to ₩11,830 over the past week.
New Risk • May 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change).
Buy Or Sell Opportunity • May 04Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 69% to ₩14,130. The fair value is estimated to be ₩11,060, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 16% per annum. Earnings are also forecast to grow by 52% per annum over the same time period.
Major Estimate Revision • Apr 24Consensus EPS estimates increase by 57%, revenue downgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from ₩579.5m to ₩564.8m. EPS estimate rose from ₩183 to ₩288. Net income forecast to grow 482% next year vs 62% growth forecast for Chemicals industry in South Korea. Consensus price target up from ₩12,000 to ₩20,000. Share price fell 5.4% to ₩13,070 over the past week.
New Risk • Apr 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.0x net interest cover). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
New Risk • Apr 02New major risk - Revenue and earnings growthEarnings have declined by 57% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Earnings have declined by 57% per year over the past 5 years.
分析記事 • Jan 28Foosung Co., Ltd. (KRX:093370) Not Lagging Industry On Growth Or PricingWhen you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...
分析記事 • Oct 28Revenues Tell The Story For Foosung Co., Ltd. (KRX:093370) As Its Stock Soars 62%Despite an already strong run, Foosung Co., Ltd. ( KRX:093370 ) shares have been powering on, with a gain of 62% in the...
New Risk • Oct 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change).
お知らせ • Oct 24Foosung Co., Ltd. announced that it expects to receive KRW 27 billion in fundingFoosung Co., Ltd. announced private placement of Series 2 Zero Coupon Registered Unsecured Private Convertible Bonds due November 05, 2030 for gross proceeds of KRW 27,000,000,000 on October 23, 2025. The transaction includes participation from Heimdall No.2 PEF for KRW 20,000,000,000 and Fluoro Mateiral New Technology Fund for KRW 7,000,000,000. The bonds bear no interest rate and have a yield to maturity rate of 5.7%. The bonds will mature on November 05, 2030. The bonds are 100% convertible into 3,937,582 shares at a conversion price of KRW 6,857 from the conversion period of November 05, 2026 to October 05, 2030. The bonds have a restriction period of 1 year. The transaction is approved by board of directors of the company and is expected to close on November 05, 2025.
分析記事 • Oct 17There's Been No Shortage Of Growth Recently For Foosung's (KRX:093370) Returns On CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
New Risk • Sep 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.7x net interest cover). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
分析記事 • Aug 18Foosung Co., Ltd. (KRX:093370) Stocks Shoot Up 30% But Its P/S Still Looks ReasonableKOSE:A093370 1 Year Share Price vs Fair Value Explore Foosung's Fair Values from the Community and select yours Despite...
分析記事 • Aug 14Is Foosung (KRX:093370) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Jun 10Potential Upside For Foosung Co., Ltd. (KRX:093370) Not Without RiskThere wouldn't be many who think Foosung Co., Ltd.'s ( KRX:093370 ) price-to-sales (or "P/S") ratio of 1.2x is worth a...
Major Estimate Revision • May 02Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩567.0m to ₩550.9m. Now expected to report a loss of ₩49.00 per share instead of ₩69.00 per share profit previously forecast. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩14,000 to ₩10,000. Share price was steady at ₩4,400 over the past week.
Reported Earnings • Mar 21Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: ₩668 loss per share (further deteriorated from ₩556 loss in FY 2023). Revenue: ₩437.8b (down 16% from FY 2023). Net loss: ₩69.4b (loss widened 29% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
分析記事 • Mar 18Would Foosung (KRX:093370) Be Better Off With Less Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Feb 19Foosung Co., Ltd., Annual General Meeting, Mar 25, 2025Foosung Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 72-37, hyundaikia-ro, paltan-myeon, gyeonggi-do, hwaseong South Korea
New Risk • Jan 24New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risk High level of debt (67% net debt to equity).
分析記事 • Nov 23The Price Is Right For Foosung Co., Ltd. (KRX:093370)When you see that almost half of the companies in the Chemicals industry in Korea have price-to-sales ratios (or "P/S...
分析記事 • Aug 05Foosung Co., Ltd.'s (KRX:093370) Share Price Is Still Matching Investor Opinion Despite 29% SlumpThe Foosung Co., Ltd. ( KRX:093370 ) share price has fared very poorly over the last month, falling by a substantial...
Major Estimate Revision • May 24Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩612.4m to ₩516.6m. Forecast loss of -₩107, down from profit of ₩91.00 per share profit previously. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩20,000 to ₩17,000. Share price fell 3.6% to ₩7,010 over the past week.
New Risk • May 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Shareholders have been diluted in the past year (14% increase in shares outstanding).
お知らせ • Jan 26Foosung Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 101.290324 billion.Foosung Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 101.290324 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 12,903,226 Price\Range: KRW 7850 Discount Per Security: KRW 39.25 Transaction Features: ESOP Related Offering; Rights Offering
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩8,620, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 28% over the past three years.
Upcoming Dividend • Dec 20Upcoming dividend of ₩20.00 per share at 0.2% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 08 April 2024. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).
New Risk • Aug 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 5.8% Last year net profit margin: 14% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). High level of non-cash earnings (26% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (5.8% net profit margin).
New Risk • Aug 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Earnings are forecast to decline by an average of 0.1% per year for the foreseeable future. High level of non-cash earnings (22% accrual ratio).
Valuation Update With 7 Day Price Move • Mar 29Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩16,620, the stock trades at a trailing P/E ratio of 16.2x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 174% over the past three years.
Reported Earnings • Mar 24Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩1,047 (up from ₩244 in FY 2021). Revenue: ₩610.6b (up 60% from FY 2021). Net income: ₩97.0b (up 330% from FY 2021). Profit margin: 16% (up from 5.9% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Dec 21Upcoming dividend of ₩15.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 07 April 2023. Payout ratio is a comfortable 2.0% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Buying Opportunity • Sep 28Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 32%. The fair value is estimated to be ₩15,184, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last 3 years. Earnings per share has grown by 75%. Revenue is forecast to grow by 37% in 2 years. Earnings is forecast to grow by 58% in the next 2 years.
Buying Opportunity • Aug 05Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be ₩20,863, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 45% in 2 years. Earnings is forecast to grow by 88% in the next 2 years.
Buying Opportunity • Jul 12Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 23%. The fair value is estimated to be ₩20,767, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 37%. Revenue is forecast to grow by 45% in 2 years. Earnings is forecast to grow by 88% in the next 2 years.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩17,900, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 157% over the past three years.
Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 29% share price gain to ₩26,250, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 263% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩19,850, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 141% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩18,551 per share.
分析記事 • May 09Are Investors Undervaluing Foosung Co., Ltd. (KRX:093370) By 46%?Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Foosung Co., Ltd...
分析記事 • Apr 19Foosung (KRX:093370) Use Of Debt Could Be Considered RiskyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Mar 25Full year 2020 earnings released: EPS ₩65.00 (vs ₩87.00 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩261.6b (up 5.1% from FY 2019). Net income: ₩5.99b (down 26% from FY 2019). Profit margin: 2.3% (down from 3.3% in FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
分析記事 • Mar 08Here's What To Make Of Foosung's (KRX:093370) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
お知らせ • Feb 27Foosung Co., Ltd., Annual General Meeting, Mar 30, 2021Foosung Co., Ltd., Annual General Meeting, Mar 30, 2021, at 10:00 Korea Standard Time.
分析記事 • Feb 14Is Foosung's (KRX:093370) 184% Share Price Increase Well Justified?The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
分析記事 • Jan 24Are Investors Undervaluing Foosung Co., Ltd. (KRX:093370) By 25%?How far off is Foosung Co., Ltd. ( KRX:093370 ) from its intrinsic value? Using the most recent financial data, we'll...
Is New 90 Day High Low • Jan 19New 90-day high: ₩13,150The company is up 41% from its price of ₩9,300 on 21 October 2020. The South Korean market is up 26% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 35% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩17,381 per share.
分析記事 • Jan 02Foosung (KRX:093370) Has A Somewhat Strained Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Dec 18New 90-day high: ₩11,500The company is up 10.0% from its price of ₩10,500 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 18% over the same period.
分析記事 • Dec 06Do Institutions Own Foosung Co., Ltd. (KRX:093370) Shares?A look at the shareholders of Foosung Co., Ltd. ( KRX:093370 ) can tell us which group is most powerful. Institutions...